News Home

Should Biotechnology Stock Reata Pharmaceuticals Inc (RETA) Be in Your Portfolio Monday?

Monday, May 16, 2022 01:42 PM | InvestorsObserver Analysts
Should Biotechnology Stock Reata Pharmaceuticals Inc (RETA) Be in Your Portfolio Monday?

Reata Pharmaceuticals Inc (RETA) is around the top of the Biotechnology industry according to InvestorsObserver. RETA received an overall rating of 68, which means that it scores higher than 68 percent of all stocks. Reata Pharmaceuticals Inc also achieved a score of 91 in the Biotechnology industry, putting it above 91 percent of Biotechnology stocks. Biotechnology is ranked 68 out of the 148 industries.

Overall Score - 68
RETA has an Overall Score of 68. Find out what this means to you and get the rest of the rankings on RETA!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Reata Pharmaceuticals Inc Stock Today?

Reata Pharmaceuticals Inc (RETA) stock is trading at $25.42 as of 1:41 PM on Monday, May 16, an increase of $0.88, or 3.59% from the previous closing price of $24.54. The stock has traded between $24.03 and $26.50 so far today. Volume today is light. So far 180,162 shares have traded compared to average volume of 514,679 shares. Click Here to get the full Stock Report for Reata Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App